Chemomab amends domestication merger terms ahead of planned Scipher deal
CMMB•Chemomab amended the formula-based exchange ratio for its U.S. redomiciling ahead of its planned merger with Scipher, targeting 10 million parent-company shares outstanding at closing. The change leaves consideration and the relative ownership split unchanged; the deal remains targeted for the fourth quarter of 2026.
1. Merger terms revised
The amendment sets a formula-based exchange ratio for Chemomab’s redomiciling into the U.S. and aims to fix the number of parent-company shares issued so 10 million are outstanding at closing. The transaction’s consideration and relative ownership split between Chemomab and Scipher holders remain unchanged.
